Cargando…
Anti‐EGFR Therapy in Small Bowel Adenocarcinoma
Small bowel adenocarcinoma is a rare disease occurring 50–100‐fold less often than colorectal cancer. This commentary describes similarities and differences between the two diseases and related results of recent clinical trials.
Autores principales: | Safyan, Rachael A., Neugut, Alfred I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905695/ https://www.ncbi.nlm.nih.gov/pubmed/29438094 http://dx.doi.org/10.1634/theoncologist.2017-0688 |
Ejemplares similares
-
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020) -
Cancer as a Disease of the Cell
por: Neugut, Alfred I
Publicado: (2022) -
Curative, Life‐Extending, and Palliative Chemotherapy: New Outcomes Need New Names
por: Neugut, Alfred I., et al.
Publicado: (2017) -
The Looming Threat: Cancer in Sub‐Saharan Africa
por: Neugut, Alfred I., et al.
Publicado: (2021) -
Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)